全文获取类型
收费全文 | 1312180篇 |
免费 | 95565篇 |
国内免费 | 2074篇 |
专业分类
耳鼻咽喉 | 18608篇 |
儿科学 | 43595篇 |
妇产科学 | 38709篇 |
基础医学 | 191367篇 |
口腔科学 | 35891篇 |
临床医学 | 114273篇 |
内科学 | 257546篇 |
皮肤病学 | 26882篇 |
神经病学 | 102632篇 |
特种医学 | 50711篇 |
外国民族医学 | 367篇 |
外科学 | 200897篇 |
综合类 | 26844篇 |
现状与发展 | 1篇 |
一般理论 | 349篇 |
预防医学 | 97846篇 |
眼科学 | 29412篇 |
药学 | 99903篇 |
1篇 | |
中国医学 | 2529篇 |
肿瘤学 | 71456篇 |
出版年
2018年 | 12839篇 |
2016年 | 10857篇 |
2015年 | 12486篇 |
2014年 | 17221篇 |
2013年 | 26317篇 |
2012年 | 36341篇 |
2011年 | 38913篇 |
2010年 | 22811篇 |
2009年 | 21455篇 |
2008年 | 37523篇 |
2007年 | 40545篇 |
2006年 | 41043篇 |
2005年 | 40274篇 |
2004年 | 38646篇 |
2003年 | 37424篇 |
2002年 | 36886篇 |
2001年 | 58321篇 |
2000年 | 59781篇 |
1999年 | 50947篇 |
1998年 | 14640篇 |
1997年 | 13116篇 |
1996年 | 13321篇 |
1995年 | 12545篇 |
1994年 | 11957篇 |
1993年 | 11047篇 |
1992年 | 41101篇 |
1991年 | 40467篇 |
1990年 | 39975篇 |
1989年 | 38796篇 |
1988年 | 36194篇 |
1987年 | 35427篇 |
1986年 | 33803篇 |
1985年 | 32213篇 |
1984年 | 24018篇 |
1983年 | 20895篇 |
1982年 | 12459篇 |
1981年 | 11022篇 |
1979年 | 22674篇 |
1978年 | 15908篇 |
1977年 | 13768篇 |
1976年 | 12991篇 |
1975年 | 14225篇 |
1974年 | 16697篇 |
1973年 | 16084篇 |
1972年 | 15332篇 |
1971年 | 14237篇 |
1970年 | 13226篇 |
1969年 | 12740篇 |
1968年 | 11982篇 |
1967年 | 10481篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
3.
4.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
5.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
6.
7.
8.
9.
10.